Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
O-GlcNAcase inhibitor
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "O-GlcNAcase inhibitor" in MCE Product Catalog:
56
6
6 Cited Publications
Target:
Research Areas:
(Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form .
Target:
Research Areas:
MK-8719 is a highly potent and selective O-GlcNAcase (OGA) inhibitor (Ki=7.9 nM for hOGA) with excellent CNS penetration .
Synonyms: LY3372689
Target:
Research Areas:
Ceperognastat (LY3372689) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. Ceperognastat can be used for tauopathies research, including Alzheimer’s disease .
Synonyms: ASN90
Target:
Research Areas:
Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .
Synonyms: O-GlcNAcase-IN-1
Target:
Research Areas:
TP-040 (O-GlcNAcase-IN-1), a chemical probe, is a potent and novel OGA inhibitor with an IC50 value of 46 nM.
Cat. No.: HY-176852
CAS No.: 2760514-33-6
Target:
Research Areas:
O-GlcNAcase-IN-3 (Compound I) is an OGA inhibitor. O-GlcNAcase-IN-3 can be used for Alzheimer's Disease (AD) research .
Cat. No.: HY-178510
Target:
Research Areas:
JQ1-S (GlcNAc) Cq is a sugar-modified BRD4 PROTAC degrader with a DC50 of 2.1 μM. JQ1-S (GlcNAc) Cq inhibits the formation of the ternary complex between CRBN and BRD4 (BD1/BD2). JQ1-S (GlcNAc) Cq serves as a substrate for O-GlcNAcase, which cleaves its O-GlcNAc domain to restore binding ability with CRBN, thereby forming a BRD4-containing ternary complex and triggering ubiquitination and proteasomal degradation of BRD4. JQ1-S (GlcNAc) Cq is applicable for cancer research .
Cat. No.: HY-144682
CAS No.: 3085990-58-2
Target:
Research Areas:
O-GlcNAcase-IN-4 is a O-GlcNAcase inhibitor extracted from patent WO2018140299A1 Formulaic Ic. O-GlcNAcase-IN-4 can be used for the research of neurodegenerative diseases and disorders, such as Alzheimer's disease .
Cat. No.: HY-144681A
CAS No.: 2241514-58-7
Synonyms: rel-LY3372689
Target:
Research Areas:
rel-Ceperognastat (rel-LY3372689) (Compound Formula Ic) is a O-GlcNAcase (OGA) inhibitor that can be used to study the neurodegenerative diseases and disorders, such as Alzheimer's disease .
Cat. No.: HY-161953
Target:
Research Areas:
O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects .
Cat. No.: HY-181600
Target:
Research Areas:
O-GlcNAcase-IN-4 (compound T-110) is a O-GlcNAcase inhibitor with an IC50 of 11.59 nM. O-GlcNAcase-IN-4 modulates the activity of O-GlcNAcase. O-GlcNAcase-IN-4 is applicable to the research of neurodegenerative diseases and disorders, Alzheimer's disease, and tau-mediated neurodegenerative diseases or disorders .
Cat. No.: HY-108241R
CAS No.: 132489-69-1
Target:
Research Areas:
(Z)-PUGNAc (Standard) is the analytical standard of (Z)-PUGNAc (HY-108241). This product is intended for research and analytical applications. (Z)-PUGNAc is a potent O-GlcNAcase inhibitor. (Z)-PUGNAc is a vastly more potent inhibitor of O-GlcNAcase than the E form .
Cat. No.: HY-183557
CAS No.: 2407072-65-3
Target:
Research Areas:
O-GlcNAcase-IN-6 is an orally active, blood-brain barrier-permeable O-GlcNAcase (OGA) inhibitor with an IC50 of 5.4 nM. O-GlcNAcase-IN-6 inhibits OGA activity, thereby increasing the level of O-GlcNAc glycosylation in brain tissues. O-GlcNAcase-IN-6 can be used for the research of Alzheimer's disease .
Cat. No.: HY-185146
CAS No.: 690215-80-6
Target:
Research Areas:
O-GlcNAcase-IN-5 (Compound 1) is a selective O-GlcNAcase inhibitor. O-GlcNAcase-IN-5 can prevent the enzyme from removing the O-GlcNAc modification on tau protein, thus avoiding excessive phosphorylation of tau protein. O-GlcNAcase-IN-5 can be used for the research of Alzheimer's disease .
Cat. No.: HY-12588R
CAS No.: 1009816-48-1
Target:
Research Areas:
Thiamet G (Standard) is the analytical standard of Thiamet G (HY-12588). This product is intended for research and analytical applications. Thiamet G is a potent and selective inhibitor of O-GlcNAcase (OGA), which acts to remove O-GlcNAc from modified proteins, with Ki of 20 nM for human OGA.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
